E.L. Buchmeier

机构：University Hospital Cologne

发表论文 27 篇 · 总被引 433 次 · h-index 6

代表论文

• Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (2024 · New England Journal of Medicine · 被引 307)
• ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC). (2024 · Journal of Clinical Oncology · 被引 48)
• 1988MO Recruitment discontinuation in TREASURE trial (thoracic radiotherapy with atezolizumab in small cell lung cancer extensive disease) due to unexpected safety data (2023 · Annals of Oncology · 被引 17)
• LBA81 Durvalumab (D) as consolidation therapy in limited-stage SCLC (LS-SCLC): Outcomes by prior concurrent chemoradiotherapy (cCRT) regimen and prophylactic cranial irradiation (PCI) use in the ADRIATIC trial (2024 · Annals of Oncology · 被引 14)
• LBA65 Neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery (Sx) and adjuvant D or CRT and consolidation D in patients (pts) with resectable or borderline resectable stage IIB–IIIB NSCLC: Interim analysis (IA) of the phase II MDT-BRIDGE study (2025 · Annals of Oncology · 被引 6)
• Innovative therapeutic cancer vaccine PDC∗lung01 with or without anti-PD-1: an open-label, dose-escalation phase I/II study in non-small-cell lung cancer (2025 · ESMO Open · 被引 5)